I think they’re saying the results can’t be used to determine disease progression and can’t be used as a basis to move to Phase 2. The following sentence says:
”PharmAust intends to continue with MPL dose escalation for Cohorts 3 and 4 to determine the optimum dosage for Phase 2.”
Clearly saying more work needs to be done before moving to Phase 2.
I do think it’s poorly worded for a layman to easily understand.
I think they’re saying the results can’t be used to determine...
-
- There are more pages in this discussion • 84 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
20.8¢ |
Change
-0.003(1.19%) |
Mkt cap ! $82.15M | |||
| Open | High | Low | Value | Volume |
| 20.5¢ | 20.8¢ | 20.5¢ | $8.737K | 42.42K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 9 | 286120 | 20.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 21.0¢ | 89005 | 5 |
View Market Depth
| Last trade - 10.24am 26/06/2024 (20 minute delay) ? |
| PAA (ASX) Chart |